U.S. markets open in 4 hours 14 minutes

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2017-0.0013 (-0.64%)
At close: 3:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.2030
Open0.1962
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1962 - 0.2051
52 Week Range0.0940 - 0.4400
Volume123,124
Avg. Volume280,130
Market Cap80.991M
Beta (5Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0880
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TETRA BIO PHARMA INC
    CPE: Lowering target price to $11.00CALLON PETROLEUM CO has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • PR Newswire

    Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it received the Scientific Advice Assessment (SAA) Report from the Malta Medicines Authority. Overall, the SAA Report provided positive feedback on Tetra's drug development plan for QIXLEEF™ and eligibility for submitting a Marketing Authorization Application (MAA) under Directive 2001/83/EC (Directive). QIXLEEF™ is the

  • CNW Group

    Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

    Tetra Bio-Pharma Inc ("Tetra" or the Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No. PCT/CA2021/050886, with a filing date of June 28, 2021. Through the Tetra partnership with Thorne HealthTech, a submission to the U.S. Food and Drug Administration for Generally Recognized as Safe (GRAS) is being pursued. GRAS st

  • PR Newswire

    Tetra Bio-Pharma Engages Christine Caron as Patient Partner

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today it has engaged Christine Caron as Patient Partner to support significant and active collaboration in research, knowledge translation, and patient engagement within the pain and Sepsis communities.